Why Jazz Pharmaceuticals is back on investors’ radar

Boehringer Ingelheim’s new clinical collaboration with Jazz Pharmaceuticals (JAZZ), pairing zongertinib with zanidatamab for HER2-positive breast cancer, is drawing fresh attention to Jazz’s oncology pipeline and its broader stock story.

Jazz’s shares have been relatively flat in the very short term, but a 23.44% 90 day share price return alongside a 40.12% one year total shareholder return suggests building momentum as investors react to the Boehringer Ingelheim collaboration and the oncology pipeline’s visibility.

If the Jazz news has you looking across biotech, this is a good moment to scan healthcare stocks for other healthcare names that fit your investing checklist.

With Jazz delivering a 40.12% one year total return, trading at US$171 against an average analyst target of US$216.44 and screening with a value score of 6, you have to ask: is there still upside here, or is the market already baking in the oncology pipeline’s future potential?

Most Popular Narrative: 19.7% Undervalued

At $171, the most followed narrative pegs Jazz Pharmaceuticals’ fair value at $213, which puts the current share price at a clear discount on that view.

Ongoing investments in R&D, commercialization infrastructure, and international launches (such as rolling out Ziihera in BTC across Europe) are contributing to lower barriers to entry in new geographies as healthcare access expands, with the company positioned for steady long term market share and revenue growth.

Curious what has to happen for that valuation to stack up? Revenue would need to climb at a steady pace, margins would need to reset higher, and a future earnings multiple would need to reflect meaningful execution. The narrative connects all three in a precise way, but the exact numbers might surprise you.

Result: Fair Value of $213 (UNDERVALUED)

However, the picture is not one way. Looming patent expiries in the oxybate franchise and high debt levels are both capable of quickly challenging that undervalued story.

Build Your Own Jazz Pharmaceuticals Narrative

If you see the numbers differently or prefer to test the assumptions yourself, you can build a fresh Jazz view in just a few minutes: Do it your way.

A great starting point for your Jazz Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Jazz has your interest, do not stop here. Your next move could come from spotting a pattern across other stocks using focused screeners.

• Look at future growth potential by scanning these 24 AI penny stocks that sit at the intersection of technology and real-world adoption.
• Review these 12 dividend stocks with yields > 3% to see which companies currently offer yields above 3%.
• Explore these 19 cryptocurrency and blockchain stocks, where listed plays on digital assets and blockchain infrastructure are grouped in one place.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.